Related references
Note: Only part of the references are listed.Antinociceptive, anxiolytic, and depression-like effects of hydrogen sulfide, nitric oxide, and carbon monoxide in rats and the role of opioidergic and serotonergic systems in antinociceptive activity
Veysel Baskin et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2022)
Hippocampal Over-Expression of Cyclooxygenase-2 (COX-2) Is Associated with Susceptibility to Stress-Induced Anhedonia in Mice
Tatyana Strekalova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Pentadecapeptide BPC 157 and the central nervous system
Jaksa Vukojevic et al.
NEURAL REGENERATION RESEARCH (2022)
Protein kinase C gamma in cerebellar Purkinje cells regulates Ca2+-activated large-conductance K+ channels and motor coordination
Masashi Watanave et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome
Predrag Sikiric et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2022)
Uncovering associations between mental illness diagnosis, nitric oxide synthase gene variation, and peripheral nitric oxide concentration
Rhiannon McNeill et al.
BRAIN BEHAVIOR AND IMMUNITY (2022)
The possible role of nitric oxide signaling and NMDA receptors in allopurinol effect on maximal electroshock- and pentylenetetrazol-induced seizures in mice
Nastaran Rahimi et al.
NEUROSCIENCE LETTERS (2022)
Gut permeability and its clinical relevance in schizophrenia
Ikki Ishida et al.
NEUROPSYCHOPHARMACOLOGY REPORTS (2022)
New 2,3-Benzodiazepine Derivative: Synthesis, Activity on Central Nervous System, and Toxicity Study in Mice
Amal Amaghnouje et al.
PHARMACEUTICALS (2021)
Protein Kinase C-Gamma Knockout Mice Show Impaired Hippocampal Short-Term Memory While Preserved Long-Term Memory
Maria Gomis-Gonzalez et al.
MOLECULAR NEUROBIOLOGY (2021)
Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia
Andrea Zemba Cilic et al.
BEHAVIOURAL BRAIN RESEARCH (2021)
Synergistic effect between quinpirole and L-NAME as well as sulpiride and L-arginine on the modulation of anxiety and memory processes in the 6-OHDA mouse model of Parkinson's disease: An isobologram analysis
Mohammad-Reza Zarrindast et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2021)
Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia
Michael Maes et al.
MOLECULAR NEUROBIOLOGY (2021)
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Stephen K. Brannan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157
Sanja Strbe et al.
BIOMEDICINES (2021)
Coexpression of the discoidin domain receptor 1 gene with oligodendrocyte-related and schizophrenia risk genes in the developing and adult human brain
Gerard Muntane et al.
BRAIN AND BEHAVIOR (2021)
D-Serine: A Cross Species Review of Safety
Amir Meftah et al.
FRONTIERS IN PSYCHIATRY (2021)
BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection
Jong M. Park et al.
CURRENT PHARMACEUTICAL DESIGN (2020)
Current understanding on the role of nitric oxide and therapeutic potential of NO supplementation in schizophrenia
SeungJu Jackie Oh et al.
SCHIZOPHRENIA RESEARCH (2020)
Induction of inducible nitric oxide synthase expression in activated microglia and astrocytes following pre- and postnatal immune challenge in an animal model of schizophrenia
Awatef Esshili et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)
The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
Jaksa Vukojevic et al.
BRAIN AND BEHAVIOR (2020)
Activation of tyrosine phosphatase PTP1B in pyramidal neurons impairs endocannabinoid signaling by tyrosine receptor kinase trkB and causes schizophrenia-like behaviors in mice
Zhaohong Qin et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
Chuanyang Xu et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2020)
Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway
Ming-Jer Hsieh et al.
SCIENTIFIC REPORTS (2020)
Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157
Hailu Wu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2020)
Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
Christoph U. Correll et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2020)
The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats
Elli Zoupa et al.
NEUROPHARMACOLOGY (2019)
Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells
Xi-Yu Wang et al.
NEUROSCIENCE BULLETIN (2019)
Nitric oxide signalling and antidepressant action revisited
Samia R. L. Joca et al.
CELL AND TISSUE RESEARCH (2019)
Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia
B. Galling et al.
ACTA PSYCHIATRICA SCANDINAVICA (2018)
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
Sven Seiwerth et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
Marc Krause et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2018)
L-Arginine Add-On Treatment for Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
Yasemin Kocyigit et al.
TURK PSIKIYATRI DERGISI (2018)
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Ming-Jer Hsieh et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2017)
Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study
Farzin Rezaei et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2017)
Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial
Soode Tajik-Esmaeeli et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2017)
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
Gyorgy Nemeth et al.
LANCET (2017)
The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats
Aikaterini Trevlopoulou et al.
PSYCHOPHARMACOLOGY (2016)
The Role of Nitric Oxide Synthase Inhibitors in Schizophrenia
Nikolaos Pitsikas
CURRENT MEDICINAL CHEMISTRY (2016)
Combined serotonin (5-HT)1A agonism, 5-HT2A and dopamine D2 receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats
Yoshihiro Oyamada et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia
Ludmyla Kandratavicius et al.
BMC NEUROSCIENCE (2015)
Hint1 knockout results in a compromised activation of protein kinase C gamma in the brain
Fan Zhang et al.
BRAIN RESEARCH (2015)
The Flaws and Human Harms of Animal Experimentation
Aysha Akhtar
CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS (2015)
The role of nitric oxide donors in schizophrenia: Basic studies and clinical applications
Nikolaos Pitsikas
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Neuronal nitric oxide synthase (NOS1) and its adaptor, NOS1AP, as a genetic risk factors for psychiatric disorders
F. Freudenberg et al.
GENES BRAIN AND BEHAVIOR (2015)
Clinical management of negative symptoms of schizophrenia: An update
Evangelia M. Tsapakis et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro
Tonglie Huang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Predrag Sikiric et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Mark J. Milian et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
Chung-Hsun Chang et al.
MOLECULES (2014)
The metabotropic glutamate 2/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety
Vasilios Grivas et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases
Robert A. Lasser et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine
Bruna Mara Machado Ribeiro et al.
SCHIZOPHRENIA RESEARCH (2013)
Variant Brain-Derived Neurotrophic Factor (Valine66Methionine) Polymorphism Contributes to Developmental and Estrous Stage-Specific Expression of Anxiety-Like Behavior in Female Mice
Kevin G. Bath et al.
BIOLOGICAL PSYCHIATRY (2012)
Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
Hans-Gert Bernstein et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2011)
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chung-Hsun Chang et al.
JOURNAL OF APPLIED PHYSIOLOGY (2011)
Effects of the nitric oxide synthase inhibitor L-NAME on different memory components as assessed in the object recognition task in the rat
Antonios Boultadakis et al.
BEHAVIOURAL BRAIN RESEARCH (2010)
Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia
Daniel Martins-de-Souza et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2010)
Concepts of neural nitric oxide-mediated transmission
John Garthwaite
EUROPEAN JOURNAL OF NEUROSCIENCE (2008)
Effects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory
N. Pitsikas et al.
NEUROSCIENCE (2008)
Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression
Vanesa Ivetic Tkalcevic et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Kindling epileptogenesis in immature rats leads to persistent depressive behavior
Andrey Mazarati et al.
EPILEPSY & BEHAVIOR (2007)
The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats
Eliza Koros et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS
P Willner
NEUROPSYCHOBIOLOGY (2005)
Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain:: α-methyl-L-tryptophan autoradiographic measurements
Y Tohyama et al.
LIFE SCIENCES (2004)
Role of nitric oxide in experimental models of psychosis in rats
M Gupta et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2001)
Share Paper
